Akers Biosciences, Inc. (AKER) SEC Filing 8-K Material Event for the period ending Friday, October 19, 2018

Akers Biosciences, Inc.

CIK: 1321834 Ticker: AKER

View differences made from one to another to evaluate Akers Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Akers Biosciences, Inc..


Assess how Akers Biosciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Akers Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Akers Biosciences, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AKER
CIK: 1321834
Form Type: 8-K Corporate News
Accession Number: 0001493152-18-014649
Submitted to the SEC: Fri Oct 19 2018 8:45:21 AM EST
Accepted by the SEC: Fri Oct 19 2018
Period: Friday, October 19, 2018
Industry: In Vitro And In Vivo Diagnostic Substances
  1. Bylaw Change
  2. Event for Officers
  3. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: